SAN FRANCISCO, CA and VANCOUVER, May 24, 2017 /CNW/ - Innovative Targeting Solutions Inc. (ITS) today announced the successful achievement of three milestones from its collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration utilizes Innovative Targeting Solutions' proprietary HuTARG™ research platform to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer. The HuTARG™ protein engineering platform is able to engineer both T-cell receptors and fully human antibodies that bind major histocompatibility complex (MHC)/peptide complexes displaying fragments of intracellular proteins of interest.
"We are extremely pleased with the progress of the collaboration", said Paul Kang, CSO Innovative Targeting Solutions. "The HuTARG™ platform continues to exceed expectations and it is especially rewarding to see the speed and quality of biologics we were able to create on such a challenging class of targets."
Under the terms of the agreement, ITS is eligible for payments associated with the achievement of specified milestones. ITS is also eligible to receive royalty payments on sales of any products. Further details of the agreement are not being disclosed.
About Innovative Targeting Solutions Inc.
Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation protein engineering platform for the generation of fully human antibody and T-cell receptor based therapeutics using its proprietary HuTARG™ technology. The HuTARG™ technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit www.innovativetargeting.com
SOURCE Innovative Targeting Solutions Inc.
For further information: Media contact: Heather McKenzie-Beck, Hill+Knowlton Strategies, 604-808-1111, email@example.com